KNI 272

Drug Profile

KNI 272

Alternative Names: Kynostatin 272

Latest Information Update: 23 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Energy Corporation
  • Class Oligopeptides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections; HIV-1 infections

Most Recent Events

  • 02 May 2001 A study has been added to the adverse events, pharmacokinetics and Viral Infections therapeutic trials sections
  • 11 Feb 2000 A phase I study has been added to the pharmacokinetics, adverse events and therapeutic trials sections
  • 29 Dec 1998 A study has been added to the antimicrobial activities and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top